塔拉塔马布:第一次批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.
Drugs
|July 18, 2024
概括
塔拉塔马布是一种新的双特异性抗体,用于扩散阶段小细胞肺癌 (SCLC). 它针对三角形状联体3 (DLL3) 和CD3T细胞,导致瘤细胞死亡并获得美国批准.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药物开发 药物开发
背景情况:
- 小细胞肺癌 (SCLC) 对广泛阶段疾病的治疗选择有限.
- 德尔塔样联体3 (DLL3) 是一种在SCLC细胞上表达的标.
- T细胞参与剂为癌症免疫疗法提供了一种新的方法.
研究的目的:
- 总结一下tarlatamab的发展里程碑.
- 为了强调tarlatamab在广泛阶段SCLC (ES-SCLC) 的首次批准.
主要方法:
- 塔拉塔马布是一种双特异性抗体,可以将CD3T细胞与DLL3表达瘤细胞交配.
- 第二阶段的DeLLphi-301研究评估了ES-SCLC患者的tarlatamab.
- 机制涉及T细胞激活和细胞因子释放,导致瘤细胞死亡.
主要成果:
- 塔拉塔马布在2024年5月获得美国加速批准,用于ES-SCLC的成年人.
- 批准是基于DeLLphi-301研究的整体反应率和反应持续时间.
- 其他国家正在进行监管审查,临床研究正在进行中.
结论:
- 塔拉塔马布代表了针对复发性/耐药性ES-SCLC的第一类疗法.
- 药物的机制针对瘤细胞上的DLL3和T细胞上的CD3.
- 继续进行临床试验是必要的,以确认临床益处.
相关概念视频
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
